The U.S. Food and Drug Administration (FDA) has awarded Anivive, a pet health tech company, a $500,000 USD grant to continue research on LAVERDIA™ -CA1 (verdinexor) and its effect on treating canine cancer. As one of four companies selected for the MUMS grant, Anivive is partnering with Tufts University to enroll canine patients for a double-masked, randomized and placebo-controlled multi-site study to test the efficacy and safety of LAVERDIA™ -CA1 for treating canine lymphoma. David Bruyette, DVM, DACVIM, Anivive’s CMO, stated, “We are honored to be a recipient of this grant from the FDA. These funds will help to defray some of the costs associated with this exciting work.”
Read more here.
More on: News Regulatory